Galmed Pharmaceuticals (GLMD)
NASDAQ:GLMD
Want to see GLMD full AI Analyst Report?
Total Valuation
Galmed Pharmaceuticals has a market cap or net worth of $4.14M. The enterprise value is -$550.07K.
Market Cap$4.14M
Enterprise Value-$550.07K
Share Statistics
Galmed Pharmaceuticals has 6,599,654 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,599,654
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Galmed Pharmaceuticals’s return on equity (ROE) is -0.65 and return on invested capital (ROIC) is -53.92%.
Return on Equity (ROE)-0.65
Return on Assets (ROA)-0.55
Return on Invested Capital (ROIC)-53.92%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee0.00
Profits Per Employee-3.44M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Galmed Pharmaceuticals is ―. Galmed Pharmaceuticals’s PEG ratio is 0.00446.
PE Ratio―
PS Ratio0.00
PB Ratio0.21
Price to Fair Value0.21
Price to FCF-0.51
Price to Operating Cash Flow-0.65
PEG Ratio0.00446
Income Statement
In the last 12 months, Galmed Pharmaceuticals had revenue of 0.00 and earned -10.31M in profits. Earnings per share was -2.39.
Revenue0.00
Gross Profit0.00
Operating Income-8.51M
Pretax Income-10.31M
Net Income-10.31M
EBITDA-8.51M
Earnings Per Share (EPS)-2.39
Cash Flow
In the last 12 months, operating cash flow was -6.32M and capital expenditures 0.00, giving a free cash flow of -6.32M billion.
Operating Cash Flow-6.32M
Free Cash Flow-6.32M
Free Cash Flow per Share-0.96
Dividends & Yields
Galmed Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.04
52-Week Price Change-62.51%
50-Day Moving Average0.62
200-Day Moving Average1.12
Relative Strength Index (RSI)62.53
Average Volume (3m)84.25K
Important Dates
Galmed Pharmaceuticals upcoming earnings date is May 20, 2026, Before Open (Confirmed).
Last Earnings DateNov 26, 2025
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Galmed Pharmaceuticals as a current ratio of 6.55, with Debt / Equity ratio of 0.00%
Current Ratio6.55
Quick Ratio6.55
Debt to Market Cap0.00
Net Debt to EBITDA0.47
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Galmed Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Galmed Pharmaceuticals EV to EBITDA ratio is 0.09, with an EV/FCF ratio of 0.12.
EV to Sales0.00
EV to EBITDA0.09
EV to Free Cash Flow0.12
EV to Operating Cash Flow0.12
Balance Sheet
Galmed Pharmaceuticals has $18.16M in cash and marketable securities with $0.00 in debt, giving a net cash position of $18.16M billion.
Cash & Marketable Securities$18.16M
Total Debt$0.00
Net Cash$18.16M
Net Cash Per Share$2.75
Tangible Book Value Per Share$3.66
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Galmed Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast74.58%